GlassScriptPhysician profile
Thomas C Pope
NPI 1689655565
$6,721.58
in general payments reported to CMS, 2019-2025
36 companies · $834 in 2025
The $834 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $875 · 2021: $988 · 2022: $820 · 2023: $1,064 · 2024: $1,097 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,656.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,229.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $567.15 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $423.88 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.80 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $338.29 | 2019-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Janssen Pharmaceuticals, INC | $300.84 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $170.64 | 2019-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $153.87 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.76 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $136.16 | 2024-2025 | Watchman Flx |
| Abbott Laboratories | $125.19 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $104.11 | 2019-2021 | |
| Corium, LLC | $104.05 | 2022-2023 | Azstarys |
| Pfizer INC. | $88.33 | 2020-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83.06 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $78.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.13 | 2020-2022 | |
| Amarin Pharma, INC. | $64.35 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.27 | 2022 | |
| Mylan Specialty L.P. | $49.09 | 2020-2021 | |
| Amgen INC. | $43.14 | 2023-2024 | Prolia, Evenity |
| Irhythm Technologies, INC. | $39.13 | 2023 | Zio Xt Patch |
| Dexcom, INC. | $36.43 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $34.73 | 2023 | Cologuard Collection Kit |
| Cranial Technologies, INC | $33.55 | 2020 | |
| Shire North American Group INC | $26.10 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.31 | 2020-2023 | Seglentis |
| Sanofi Pasteur INC. | $20.95 | 2019 | |
| Seqirus USA INC | $20.86 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Sobi, INC | $20.01 | 2022 | |
| Medicure Pharma INC. | $15.34 | 2021 | |
| Genentech USA, INC. | $15.26 | 2019 | |
| Adlon Therapeutics L.P. | $14.50 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.69 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.